Citius Pharmaceuticals, Inc. is a clinical‐stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products for hospital acute care and cancer supportive care settings. The company’s product pipeline addresses severe and often life‐threatening conditions, including catheter‐related bloodstream infections, acute respiratory distress syndrome and mucosal immunotherapy for gastrointestinal infections. By focusing on hospital‐administered therapies, Citius seeks to meet unmet medical needs where rapid intervention and novel mechanisms of action can improve patient outcomes and reduce healthcare costs.
The company’s lead product candidate, Mino‐Lok®, is an antibiotic lock solution designed to treat patients suffering from catheter‐related bloodstream infections without the need for catheter removal. Citius is also developing Mino‐Wrap®, an antibiotic‐eluting mesh intended for use in surgical wound sites to prevent post‐operative infections. In parallel, the company is advancing DSTAT®, a recombinant form of human deoxyribonuclease I for the treatment of acute respiratory distress syndrome (ARDS), and evaluating hyperimmune compounds targeting recurrent Clostridioides difficile infection under its proprietary HyperAcute® platform.
Founded in 2015 through the combination of multiple pharmaceutical ventures, Citius is headquartered in Cranford, New Jersey, and conducts clinical trials and manufacturing partnerships in the United States, with potential expansion into international markets through licensing collaborations. Since its inception, the company has pursued an asset‐centric model, favoring targeted in‐licensing of technologies and strategic alliances to accelerate development timelines and manage capital efficiently.
Under the leadership of President and Chief Executive Officer Michael Mulhern and a management team experienced in product development, regulatory affairs and commercialization, Citius Pharmaceuticals aims to navigate late‐stage clinical programs toward regulatory approval. The company continues to engage with healthcare providers, regulatory authorities and potential partners to bring its innovative therapies to the patients who need them most.
AI Generated. May Contain Errors.
Free CTXR Stock Alerts